Cargando…
A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia
(1) Background: In epidemiological terms, it has been possible to calculate the savings in health resources and the reduction in the health effects of COVID vaccines. Conducting an economic evaluation, some studies have estimated its cost-effectiveness; the vaccination shows highly favorable results...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780175/ https://www.ncbi.nlm.nih.gov/pubmed/35062719 http://dx.doi.org/10.3390/vaccines10010059 |
_version_ | 1784637771397201920 |
---|---|
author | López, Francesc Català, Martí Prats, Clara Estrada, Oriol Oliva, Irene Prat, Núria Isnard, Mar Vallès, Roser Vilar, Marc Clotet, Bonaventura Argimon, Josep Maria Aran, Anna Ara, Jordi |
author_facet | López, Francesc Català, Martí Prats, Clara Estrada, Oriol Oliva, Irene Prat, Núria Isnard, Mar Vallès, Roser Vilar, Marc Clotet, Bonaventura Argimon, Josep Maria Aran, Anna Ara, Jordi |
author_sort | López, Francesc |
collection | PubMed |
description | (1) Background: In epidemiological terms, it has been possible to calculate the savings in health resources and the reduction in the health effects of COVID vaccines. Conducting an economic evaluation, some studies have estimated its cost-effectiveness; the vaccination shows highly favorable results, cost-saving in some cases. (2) Methods: Cost–benefit analysis of the vaccination campaign in the North Metropolitan Health Region (Catalonia). An epidemiological model based on observational data and before and after comparison is used. The information on the doses used and the assigned resources (conventional hospital beds, ICU, number of tests) was extracted from administrative data from the largest primary care provider in the region (Catalan Institute of Health). A distinction was made between the social perspective and the health system. (3) Results: the costs of vaccination are estimated at 137 million euros (€48.05/dose administered). This figure is significantly lower than the positive impacts of the vaccination campaign, which are estimated at 470 million euros (€164/dose administered). Of these, 18% corresponds to the reduction in ICU discharges, 16% to the reduction in conventional hospital discharges, 5% to the reduction in PCR tests and 1% to the reduction in RAT tests. The monetization of deaths and cases that avoid sequelae account for 53% and 5% of total savings, respectively. The benefit/cost ratio is estimated at 3.4 from a social perspective and 1.4 from a health system perspective. The social benefits of vaccination are estimated at €116.67 per vaccine dose (€19.93 from the perspective of the health system). (4) Conclusions: The mass vaccination campaign against COVID is cost-saving. From a social perspective, most of these savings come from the monetization of the reduction in mortality and cases with sequelae, although the intervention is equally widely cost-effective from the health system perspective thanks to the reduction in the use of resources. It is concluded that, from an economic perspective, the vaccination campaign has high social returns. |
format | Online Article Text |
id | pubmed-8780175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87801752022-01-22 A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia López, Francesc Català, Martí Prats, Clara Estrada, Oriol Oliva, Irene Prat, Núria Isnard, Mar Vallès, Roser Vilar, Marc Clotet, Bonaventura Argimon, Josep Maria Aran, Anna Ara, Jordi Vaccines (Basel) Article (1) Background: In epidemiological terms, it has been possible to calculate the savings in health resources and the reduction in the health effects of COVID vaccines. Conducting an economic evaluation, some studies have estimated its cost-effectiveness; the vaccination shows highly favorable results, cost-saving in some cases. (2) Methods: Cost–benefit analysis of the vaccination campaign in the North Metropolitan Health Region (Catalonia). An epidemiological model based on observational data and before and after comparison is used. The information on the doses used and the assigned resources (conventional hospital beds, ICU, number of tests) was extracted from administrative data from the largest primary care provider in the region (Catalan Institute of Health). A distinction was made between the social perspective and the health system. (3) Results: the costs of vaccination are estimated at 137 million euros (€48.05/dose administered). This figure is significantly lower than the positive impacts of the vaccination campaign, which are estimated at 470 million euros (€164/dose administered). Of these, 18% corresponds to the reduction in ICU discharges, 16% to the reduction in conventional hospital discharges, 5% to the reduction in PCR tests and 1% to the reduction in RAT tests. The monetization of deaths and cases that avoid sequelae account for 53% and 5% of total savings, respectively. The benefit/cost ratio is estimated at 3.4 from a social perspective and 1.4 from a health system perspective. The social benefits of vaccination are estimated at €116.67 per vaccine dose (€19.93 from the perspective of the health system). (4) Conclusions: The mass vaccination campaign against COVID is cost-saving. From a social perspective, most of these savings come from the monetization of the reduction in mortality and cases with sequelae, although the intervention is equally widely cost-effective from the health system perspective thanks to the reduction in the use of resources. It is concluded that, from an economic perspective, the vaccination campaign has high social returns. MDPI 2021-12-31 /pmc/articles/PMC8780175/ /pubmed/35062719 http://dx.doi.org/10.3390/vaccines10010059 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article López, Francesc Català, Martí Prats, Clara Estrada, Oriol Oliva, Irene Prat, Núria Isnard, Mar Vallès, Roser Vilar, Marc Clotet, Bonaventura Argimon, Josep Maria Aran, Anna Ara, Jordi A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia |
title | A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia |
title_full | A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia |
title_fullStr | A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia |
title_full_unstemmed | A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia |
title_short | A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia |
title_sort | cost–benefit analysis of covid-19 vaccination in catalonia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780175/ https://www.ncbi.nlm.nih.gov/pubmed/35062719 http://dx.doi.org/10.3390/vaccines10010059 |
work_keys_str_mv | AT lopezfrancesc acostbenefitanalysisofcovid19vaccinationincatalonia AT catalamarti acostbenefitanalysisofcovid19vaccinationincatalonia AT pratsclara acostbenefitanalysisofcovid19vaccinationincatalonia AT estradaoriol acostbenefitanalysisofcovid19vaccinationincatalonia AT olivairene acostbenefitanalysisofcovid19vaccinationincatalonia AT pratnuria acostbenefitanalysisofcovid19vaccinationincatalonia AT isnardmar acostbenefitanalysisofcovid19vaccinationincatalonia AT vallesroser acostbenefitanalysisofcovid19vaccinationincatalonia AT vilarmarc acostbenefitanalysisofcovid19vaccinationincatalonia AT clotetbonaventura acostbenefitanalysisofcovid19vaccinationincatalonia AT argimonjosepmaria acostbenefitanalysisofcovid19vaccinationincatalonia AT arananna acostbenefitanalysisofcovid19vaccinationincatalonia AT arajordi acostbenefitanalysisofcovid19vaccinationincatalonia AT lopezfrancesc costbenefitanalysisofcovid19vaccinationincatalonia AT catalamarti costbenefitanalysisofcovid19vaccinationincatalonia AT pratsclara costbenefitanalysisofcovid19vaccinationincatalonia AT estradaoriol costbenefitanalysisofcovid19vaccinationincatalonia AT olivairene costbenefitanalysisofcovid19vaccinationincatalonia AT pratnuria costbenefitanalysisofcovid19vaccinationincatalonia AT isnardmar costbenefitanalysisofcovid19vaccinationincatalonia AT vallesroser costbenefitanalysisofcovid19vaccinationincatalonia AT vilarmarc costbenefitanalysisofcovid19vaccinationincatalonia AT clotetbonaventura costbenefitanalysisofcovid19vaccinationincatalonia AT argimonjosepmaria costbenefitanalysisofcovid19vaccinationincatalonia AT arananna costbenefitanalysisofcovid19vaccinationincatalonia AT arajordi costbenefitanalysisofcovid19vaccinationincatalonia |